+

US20020058658A1 - 8,8A-dihydroindeno[1,2-D] thiazole derivatives which are substituted in the 8A-position; processes for their preparation and their use as medicaments - Google Patents

8,8A-dihydroindeno[1,2-D] thiazole derivatives which are substituted in the 8A-position; processes for their preparation and their use as medicaments Download PDF

Info

Publication number
US20020058658A1
US20020058658A1 US09/790,911 US79091101A US2002058658A1 US 20020058658 A1 US20020058658 A1 US 20020058658A1 US 79091101 A US79091101 A US 79091101A US 2002058658 A1 US2002058658 A1 US 2002058658A1
Authority
US
United States
Prior art keywords
alkyl
phenyl
conh
compounds
coo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/790,911
Other versions
US6403624B1 (en
Inventor
Gerhard Jaehne
Matthias Gossel
Martin Bickel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BICKEL, MARTIN, GOSSEL, MATTHIAS, JAEHNE, GERHARD
Publication of US20020058658A1 publication Critical patent/US20020058658A1/en
Application granted granted Critical
Publication of US6403624B1 publication Critical patent/US6403624B1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the invention relates to polycyclic dihydrothiazoles and to their physiologically acceptable salts and physiologically functional derivatives.
  • the object of the invention is to provide compounds having a therapeutically useful anorectic action.
  • the present compounds also find use in treatment of type II diabetes and obesity.
  • R1, R1′ are independently selected from H, F, Cl, Br, I, CF 3 , NO 2 , CN, COOH, COO(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON[(C 1 -C 6 )-alkyl] 2 , (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O—(C 1 -C 6 )-alkyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ;
  • n is 0-6 and the phenyl radical may be optionally substituted up to two times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 ;
  • NH 2 NH—(C 1 -C 6 )-alkyl, N[(C 1 -C 6 )-alkyl] 2 , NH(C 1 -C 7 )-acyl, phenyl, biphenylyl, O—(CH 2 ) n -phenyl, wherein n is 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
  • any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N[(C 1 -C 6 )-alkyl] 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;
  • 1,2,3-triazol-5-yl wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or
  • tetrazol-5-yl wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl;
  • R2 is H, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (CH 2 ) n -phenyl, (CH 2 ) n -thienyl, (CH 2 ) n -pyridyl, (CH 2 ) n -furyl, C(O)—(C 1 -C 6 )-alkyl, C(O)—(C 3 -C 6 )-cycloalkyl, C(O)—(CH 2 ) n -phenyl, C(O)—(CH 2 ) n -thienyl, C(O)—(CH 2 ) n -pyridyl or C(O)—(CH 2 ) n -furyl,
  • n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl may be optionally substituted up to two times by Cl, F, CN, CF 3 , (C 1 -C 3 )-alkyl, OH or O—(C 1 -C 6 )-alkyl;
  • R3 is Cl, Br, CH 2 —COO(C 1 -C 6 )-alkyl, CH 2 —COOH or CH 2 —CONH 2 ;
  • R4 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, (C 4 -C 7 )-cycloalkenyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph or O—(C 1 -C 4 )-alkyl;
  • phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, CF 3 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ;
  • A is 0, NH, N—(C 1 -C 6 )-alkyl, NCHO, N(CO—CH 3 ), S, SO or SO 2 ;
  • R8 is (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph or O—(C 1 -C 4 )-alkyl;
  • m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, S—(C 1 -C 6 )-alkyl, SO—(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —NH 2 , (CH 2 ) n —SO 2 —N( ⁇ CH—N(CH 3 ) 2 ), (CH 2 ) n —SO 2 —NH(C 1 -C 8 )-alkyl, (CH 2 ) n —SO 2 —N[(C 1 -C 8 )
  • phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, CF 3 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ,
  • the invention also relates to pharmaceutical compositions containing the compounds of formula I and pharmaceutically acceptable carriers. Also, pharmaceutical compositions containing the compounds of formula I in combination with at least one additional anorectic agents are contemplated.
  • the invention envisages treatment of obesity via administration of compounds of formula I. Methods of treatment for type II diabetes are also contemplated. Methods of enhancing lipid metabolism can also be achieved with the compounds of formula I.
  • the invention is directed to polycyclic thiazole compounds which are anorectics and are useful in the treatment of type II diabetes and obesity.
  • the compounds have general formula (I):
  • R1, R1′ are independently selected from H, F, Cl, Br, I, CF 3 , NO 2 , CN, COOH, COO(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON[(C 1 -C 6 )-alkyl] 2 , (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O—(C 1 -C 6 )-alkyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ;
  • n is 0-6 and the phenyl radical may be optionally substituted up to two times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 ;
  • NH 2 NH—(C 1 -C 6 )-alkyl, N[(C 1 -C 6 )-alkyl] 2 , NH(C 1 -C 7 )-acyl, phenyl, biphenylyl, O—(CH 2 ) n -phenyl, wherein n is 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
  • any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N[(C 1 -C 6 )-alkyl] 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;
  • 1,2,3-triazol-5-yl wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or
  • tetrazol-5-yl wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl;
  • R2 is H, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (CH 2 ) n -phenyl, (CH 2 ) n -thienyl, (CH 2 ) n -pyridyl, (CH 2 ) n -furyl, C(O)—(C 1 -C 6 )-alkyl, C(O)—(C 3 -C 6 )-cycloalkyl, C(O)—(CH 2 ) n -phenyl, C(O)—(CH 2 ) n -thienyl, C(O)—(CH 2 ) n -pyridyl or C(O)—(CH 2 ) n -furyl,
  • n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl may be optionally substituted up to two times by Cl, F, CN, CF 3 , (C 1 -C 3 )-alkyl, OH or O—(C 1 -C 6 )-alkyl;
  • R3 is Cl, Br, CH 2 —COO(C 1 -C 6 )-alkyl, CH 2 —COOH or CH 2 —CONH 2 ;
  • R4 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, (C 4 -C 7 )-cycloalkenyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph or O—(C 1 -C 4 )-alkyl;
  • phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, CF 3 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ;
  • A is O, NH, N—(C 1 -C 6 )-alkyl, NCHO, N(CO—CH 3 ), S, SO or SO 2 ;
  • R8 is (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph or O—(C 1 -C 4 )-alkyl;
  • m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, S—(C 1 -C 6 )-alkyl, SO—(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —NH 2 , (CH 2 ) n —SO 2 —N( ⁇ CH—N(CH 3 ) 2 ), (CH 2 ) n —SO 2 —NH(C 1 -C 8 )-alkyl, (CH 2 ) n —SO 2 —N[(C 1 -C 8 )
  • phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, CF 3 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ,
  • R1, R1′ are independently selected from H, F, Cl, Br, I, CF 3 , NO 2 , CN, COOH, COO(C 1 -C 6 )-alkyl, CONH 2 , CONH(C 1 -C 6 )-alkyl, CON[(C 1 -C 6 )-alkyl] 2 , (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, O—(C 1 -C 6 )-alkyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ;
  • n is 0-6, and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl or NH 2 ;
  • NH 2 NH—(C 1 -C 6 )-alkyl, N[(C 1 -C 6 )-alkyl] 2 , NH(C 1 -C 7 )-acyl, phenyl, biphenylyl, O—(CH 2 ) n -phenyl, where n is 0-6, 1 - or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
  • any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF 3 , NO 2 , CN, OCF 3 , O—(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl, NH 2 , NH(C 1 -C 6 )-alkyl, N[(C 1 -C 6 )-alkyl] 2 , SO 2 —CH 3 , COOH, COO—(C 1 -C 6 )-alkyl or CONH 2 ;
  • 1,2,3-triazol-5-yl wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or
  • tetrazol-5-yl wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl;
  • R2 is H, (C 1 -C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (CH 2 ) n -phenyl, (CH 2 ) n -thienyl, (CH 2 ) n -pyridyl, (CH 2 ) n -furyl, C(O)—(C 1 -C 6 )-alkyl, C(O)—(C 3 -C 6 )-cycloalkyl, C(O)—(CH 2 ) n -phenyl, C(O)—(CH 2 ) n -thienyl, C(O)—(CH 2 ) n -pyridyl or C(O)—(CH 2 ) n -furyl,
  • n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl can in each case be substituted up to two times by Cl, F, CN, CF 3 , (C 1 -C 3 )-alkyl, OH or O—(C 1 -C 6 )-alkyl;
  • R3 is Cl, Br, CH 2 —COO(C 1 -C 6 )-alkyl, CH 2 —COOH or CH 2 —CONH 2 ;
  • R4 is (C 1 -C 8 )-alkyl, (C 3 -C 7 )-cycloalkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl, (C 4 -C 7 )-cycloalkenyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph or O—(C 1 -C 4 )-alkyl;
  • n is 0-6 and aryl is phenyl or 1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl, 2- or 3-thienyl and the aryl radical or heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF 3 , O—(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —NH 2 , (CH 2 ) n —SO 2 —N( ⁇ CH—N(CH 3 ) 2 ), wherein n is 0-6, NH—SO 2 —(C 1 -C 6 )-alkyl or NH—SO 2 -phenyl,
  • phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, CF 3 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ;
  • A is O, NH, (C 1 -C 6 )-alkyl or SO 2 ;
  • R8 is (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl,
  • one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , OC(O)H, O—CH 2 —Ph or O—(C 1 -C 4 )-alkyl;
  • m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl, and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF 3 , O—(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —NH 2 , (CH 2 ) n —SO 2 —N( ⁇ CH—N(CH 3 ) 2 ), wherein n is 0-6, NH—SO 2 —(C 1 -C 6 )-alkyl, NH—SO 2 -phenyl,
  • phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C 1 -C 6 )-alkyl, O—(C 1 -C 6 )-alkyl, CF 3 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 , where n is 0-6;
  • R1, R1′ are independently selected from H, F, Cl, Br, —OH, O—(C 1 -C 6 )-alkyl or (C 1 -C 6 )-alkyl,
  • R2 is H, (C 1 -C 6 )-alkyl or C(O)—(C 1 -C 6 )-alkyl;
  • R3 is Cl, Br, CH 2 —COO(C 1 -C 6 )-alkyl, CH 2 —COOH or CH 2 —CONH 2 ;
  • R4 is (C 1 -C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl,
  • n is 0-6 and aryl may be phenyl or1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl or 2- or 3-thienyl, and the aryl radical or heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF 3 , O—(C 1 -C 6 )-alkyl, SO 2 —(C 1 -C 6 )-alkyl, (CH 2 ) n —SO 2 —NH 2 , wherein n is 0-6, (C 1 -C 6 )-alkyl, COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ; or
  • A is O or SO 2 ;
  • R8 is (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl,
  • m is 0-6 and aryl is phenyl and heteroayl is thienyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF 3 , O—(C 1 -C 6 )-alkyl, SO 2 —(C 1 -C 6 )-alkyl, SO 2 —NH 2 , COOH, COO(C 1 -C 6 )-alkyl or CONH 2 ;
  • the invention relates to compounds of formula I, in the form of their racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.
  • alkyl, alkenyl and alkynyl radicals in the substituents R1, R1′, R2, R3, R4, R8 and A may be either straight-chain or branched.
  • Suitable pharmaceutically acceptable salts of the compounds according to the invention are salts of inorganic acids, including but not limited to, hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and salts of organic acids, such as, for example, acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid, tartaric acid and trifluoroacetic acid.
  • inorganic acids including but not limited to, hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid
  • organic acids such as, for example,
  • the chlorine salt is one of the preferred.
  • Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium salts and potassium salts) and alkaline earth metal salts (such as magnesium salts and calcium salts).
  • Salts having a pharmaceutically unacceptable anion are likewise included in the scope of the invention as useful intermediates for the production or purification of pharmaceutically acceptable salts and/or for use in non-therapeutic, for example in-vitro, applications.
  • pharmaceutically unacceptable anions may be useful for the separation of enantiomers and diasteromers.
  • physiologically functional derivative as used herein relates to any physiologically acceptable derivative of a compound of formula I according to the invention, for example an ester, which on administration to a mammal, such as, for example, man, is able (directly or indirectly) to form a compound of formula I or an active metabolite thereof.
  • the physiologically functional derivatives also include prodrugs of the compounds according to the invention.
  • prodrugs may be metabolized in vivo to a compound according to the invention. These prodrugs may themselves be active or inactive.
  • the compounds according to the invention may also be present in various polymorphic forms, for example as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds according to the invention are included in the scope of the invention and are a further aspect of the invention.
  • the amount of a compound according to formula (I) which is necessary to achieve the desired biological effect depends upon a number of factors, for example, the specific compound selected, the intended use, the manner of administration and the clinical condition of the patient.
  • the daily dose is in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of bodyweight, for example 3-10 mg/kg/day.
  • An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg, which may be suitably administered as an infusion of 10 ng to 100 ng per kilogram per minute.
  • Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter.
  • Individual doses may contain, for example, from 1 mg to 10 g of the active compound.
  • ampoules for injections may contain, for example, from 1 mg to 100 mg
  • orally administrable individual dose formulations such as, for example, tablets or capsules, may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg.
  • the abovementioned weight details relate to the weight of the dihydrothiazolium ion derived from the salt.
  • the compounds according to formula (I) may be used themselves as the compound, but they are preferably present in the form of a pharmaceutical composition with a tolerable excipient.
  • the excipient is a pharmaceutically acceptable excipient, this means that it is compatible with the other constituents of the composition and is not harmful to the patient's health.
  • the excipient may be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example as a tablet which may contain from 0.05% to 95% by weight of the active compound.
  • Further pharmaceutically active substances may also be present, including further compounds according to formula (I).
  • the pharmaceutical compositions according to the invention may be prepared by one of the known pharmaceutical methods, which essentially consist in mixing the constituents with pharmacologically acceptable excipients and/or auxiliaries.
  • compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (e.g. sublingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable manner of administration in each individual case is dependent on the nature and severity of the condition to be treated and on the nature of the compound according to formula (I) used in each case.
  • Sugar-coated formulations and sugar-coated delayed release formulations are also included in the scope of the invention.
  • Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate.
  • Suitable pharmaceutical compounds for oral administration may be present in separate units, such as, for example, capsules, cachets, lozenges or tablets which in each case contain a certain amount of the compound according to formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • these compositions may be prepared by any suitable pharmaceutical method which includes a step in which the active compound and the excipient (which may consist of one or more additional constituents) are brought into contact.
  • compositions are prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product is shaped, if necessary.
  • a tablet for example, may be prepared by pressing or shaping a powder or granules of the compound, if appropriate, with one or more additional constituents.
  • Pressed tablets may be prepared by tableting the compound in free-flowing form, such as, for example, in a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or one (a number of) surface-active/dispersing agent(s) in a suitable machine.
  • Shaped tablets may be prepared by shaping the pulverulent compound, moistened with an inert liquid diluent, in a suitable machine.
  • compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound according to formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic.
  • Suitable pharmaceutical compositions for parenteral administration preferably include sterile aqueous preparations of a compound according to formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also take place subcutaneously, intramuscularly or intradermally as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the obtained solution sterile and isotonic with the blood. Injectable compositions according to the invention in general contain from 0.1 to 5% by weight of the active compound.
  • Suitable pharmaceutical compositions for rectal administration are preferably present as individual dose suppositories. These may be prepared by mixing a compound according to formula (I) with one or more conventional solid excipients, for example cocoa butter, and shaping the resulting mixture.
  • Suitable pharmaceutical compositions for topical application to the skin are preferably present as ointment, cream, lotion, paste, spray, aerosol or oil.
  • Excipients which may be used are petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances.
  • the active compound is in general present in a concentration of from 0.1 to 15%, for example of from 0.5 to 2%, by weight of the composition.
  • Transdermal administration is also possible.
  • Suitable pharmaceutical compositions for transdermal administration may be present as individual patches which are suitable for long-term close contact with the epidermis of the patient.
  • patches suitably contain the active compound in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer.
  • a suitable active compound concentration is from about 1% to 35%, preferably from about 3% to 15%.
  • the active compound may be released by electrotransport or iontophoresis, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986).
  • the invention furthermore relates to a process for preparing the compounds of formula I, which comprises reaction steps according to the scheme set forth below:
  • R1 and R1′ are as defined above, are reacted with a compound of formula Z—CH 2 —COOR, in which Z is, for example, halogen or another appropriate leaving group and R is, for example, methyl or another alkyl moiety to yield a compound of formula III in which R3 is —CH 2 —COOR.
  • R4 is as defined above, to yield compounds of Formula I.
  • Compounds of Formula I in which R3 is chlorine or bromine may be prepared by reacting compounds of Formula V with a halogenating agent, such as, for example, N-chlorosuccinimide or N-bromosuccinimide.
  • the compounds of Formula I may also be present as salts with acids.
  • Suitable inorganic acids are, for example:
  • Hydrohalic acids such as hydrochloric acid and hydrobromic acid, and also sulfuric acid, phosphoric acid and amidosulfonic acid.
  • Organic acids which may be useful include, but are not limited to: formic acid, acetic acid, benzoic acid, p-toluenesulfonic acid, benzenesulfonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, citric acid, L-ascorbic acid, salicylic acid, isethionic acid, methanesulfonic acid, trifluoromethanesulfonic acid, 1,2-benzisothiazol-3(2H)-one, 6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide.
  • reaction scheme described above it is advantageous to react the compounds of Formula IV with the thioamides of Formula VI in a molar ratio of from 1:1 to 1:1.5.
  • the reaction is carried out in an inert solvent, for example, polar organic solvents, such as dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, dioxane, tetrahydrofuran, acetonitrile, nitromethane or diethylene glycol dimethyl ether.
  • polar organic solvents such as dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, dioxane, tetrahydrofuran, acetonitrile, nitromethane or diethylene glycol dimethyl ether.
  • Particularly preferred solvents include but are not limited to methyl acetate and ethyl acetate, short-chain alcohols, such as methanol, ethanol, propanol, isopropanol, and lower dialkyl ketones, such as, for example, acetone, butan-2-one or hexan-2-one.
  • reaction media mentioned may also be used; and mixtures of the solvents mentioned with solvents which, taken per se, are less suitable, such as, for example, mixtures of methanol with benzene, ethanol with toluene, methanol with diethyl ether or with tert-butyl methyl ether, ethanol with carbon tetrachloride, acetone with chloroform, dichloromethane or 1,2- dichloroethane, may also be used, where the more polar solvent in each case should be used in an excess.
  • the reactants may be suspended or dissolved in the respective reaction medium.
  • the reactants may also be reacted in the absence of a solvent, in particular if the respective thioamide has a melting point which is as low as possible.
  • the reaction which proceeds in a slightly exothermic manner, may be carried out between ⁇ 10° C. and 150° C., preferably between 30° C. and 100° C. A temperature range between 50° C. and 90° C. has generally been found to be favorable.
  • the reaction time is largely dependent on the reaction temperature and is between 2 minutes and 3 days at relatively high and relatively low temperatures, respectively. In the favorable temperature range, the reaction time is generally between 5 minutes and 48 hours.
  • the compounds of Formula I have been shown to form a poorly soluble deposit in the form of their acid addition salts, addition of a suitable precipitating agent is subsequently added.
  • a suitable precipitating agent is subsequently added.
  • Those precipitating used are, for example, hydrocarbons such as benzene, toluene, cyclohexane or heptane or carbon tetrachloride; in particular, alkyl acetates, such as ethyl acetate or n-butyl acetate, or dialkyl ethers, such as diethyl ether, diisopropyl ether, di-n-butyl ether or tert-butyl methyl ether prove particularly suitable.
  • the salts of the compounds I may be precipitated using one of the precipitating agents mentioned, if appropriate after concentration of the reaction solution. Furthermore, the solution of the reaction mixture may also be advantageously filtered into the solution of one of the precipitating agents mentioned, with stirring. Since the reaction of the compounds of formula IV with the thioamides of formula VI proceeds almost quantitavely, the crude products obtained are mostly already analytically pure.
  • reaction mixture is rendered alkaline by addition of an organic base, such as, for example, triethylamine or diisobutylamine or ammonia or morpholine or piperidine or 1,8-diazabicyclo[5.4.0]undec-7-ene, and the crude reaction product is purified chromatographically, for example on a silica gel column, after concentration.
  • organic base such as, for example, triethylamine or diisobutylamine or ammonia or morpholine or piperidine or 1,8-diazabicyclo[5.4.0]undec-7-ene
  • Suitable eluents for the chromatography are, for example, mixtures of ethyl acetate with methanol, mixtures of dichloromethane with methanol, mixtures of toluene with methanol or ethyl acetate or mixtures of ethyl acetate with hydrocarbons such as heptane.
  • an acid addition product of formula I may be obtained from the pure base of formula I thus obtained by dissolving or suspending the base in an organic protic solvent, such as methanol, ethanol, propanol or isopropanol, or in an organic aprotic solvent, such as ethyl acetate, diethyl ether, diisopropyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, acetone or butan-2-one, and then treating this mixture with an at least equimolar amount of an inorganic acid such as, for example, hydrochloric acid, dissolved in an inert solvent such as, for example, diethyl ether or ethanol, or another of the inorganic or organic acids mentioned further above.
  • an organic protic solvent such as methanol, ethanol, propanol or isopropanol
  • organic aprotic solvent such as ethyl acetate, diethyl ether,
  • the compounds of formula I may be recrystallized from an inert suitable solvent such as, for example, acetone, butan-2-one, acetonitrile or nitromethane.
  • an inert suitable solvent such as, for example, acetone, butan-2-one, acetonitrile or nitromethane.
  • a solvent such as, for example, dimethylformamide, dimethylacetamide, nitromethane, acetonitrile, preferably methanol or ethanol.
  • reaction of the compounds of formula IV with the thioamides of formula VI may also be carried out such that an at least equimolar amount of a base, such as, for example, triethylamine, is added to the reaction mixture and the resulting compounds of Formula I are then optionally converted into their acid addition products.
  • a base such as, for example, triethylamine
  • the acid addition products of Formula I may be reacted to yield the compounds of formula I (free base) by treatment with a base.
  • Suitable bases are, for example, solutions of inorganic hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or barium hydroxide, carbonates or hydrogen carbonates, such as sodium carbonate or potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, ammonia and amines, such as triethylamine, diisopropylamine, dicyclohexylamine, piperidine, morpholine, methyldicyclohexylamine.
  • inorganic hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or barium hydroxide
  • carbonates or hydrogen carbonates such as sodium carbonate or potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate
  • ammonia and amines such as triethylamine, diisopropylamine, dicyclohexylamine
  • Thioamides of formula VI are either commercially available or may be obtained, for example, by reaction of the corresponding carboxamide V with phosphorus pentasulfide in pyridine (R. N. Hurd, G. Delameter, Chem. Rev. 61, 45 (1961)), or with Lawesson's reagent in toluene, pyridine, hexamethylphosphoric triamide [Scheibye, Pedersen and Lawesson: Bull. Soc. Chim.
  • Belges 87, 229 (1978)] preferably in a mixture of tetrahydrofuran with 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,3-dimethyl-2-imidazolidinone.
  • Hydroxyl, amino or additional carbonyl functions are in this case protected using a removable protective function, such as, for example, a benzyl, tert-butyloxycarbonyl or benzyloxycarbonyl radical, or converted into an optionally cyclic acetal. Methods for this are described, for example, in Th. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, John Wiley & Sons, New York.
  • the compounds of formula I are distinguished by favorable effects on lipid metabolism; in particular, they are suitable as anorectics. Other favorable effects on lipid metabolism include lowering cholesterol or low density lipoproteins (LDL) and increasing high density lipoproteins (HDL).
  • LDL low density lipoproteins
  • HDL high density lipoproteins
  • the compounds may be employed on their own or in combination with other anorectically active compounds. Such further anorectically active compounds are mentioned, for example, in the Rote Liste, chapter 01 under slimming preparations/anorectics.
  • Examples include, but are not limited to, DECORPA ⁇ (from Pierre Fabre Pharma, common name, sterculia), XENICAL ⁇ (from Roche, common name orlistat), ANTIADIPOSITUM X-112S (from Haenseler, common name, D-norpseudoephedrin-HCl), FASUPOND ⁇ (from Eu Rho Arzneil, common name, D-norpseudoephedrin-HCl), MIRAPRONT ⁇ N (from Mack, Illert., common name, D-norpseudoephedrin-Poly(styrol, divinylbenzol) sulfonate), REGENON ⁇ l-retard (from Temmler Pharma, common name, Amfepramon-HCl), RONDIMEN ⁇ (from ASTA Medica AWD, common name, Mefenorex-HCl), TENUATE( ⁇ Retard (from Artegodan, common name, Amfepra
  • the anorectic action was tested on female NMRI mice. After withdrawal of food for 24 hours, the test preparation of the invention was administered via a stomach tube. Kept individually and with free access to drinking water, the animals were offered evaporated milk 30 minutes after the administration of the preparation. The consumption of evaporated milk was determined every half-hour for 7 hours and the general condition of the animals was observed. The measured milk consumption was compared with that of untreated control animals. TABLE 2 Anorectic action, measured as reduction of the cumulated milk consumption of treated animals compared to untreated animals.
  • the moist residue is removed from the filter using ethyl acetate, and the phases of the filtrate are separated.
  • the organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • the residue is dissolved in 120 ml of hot n-heptane; the hot solution is filtered through a pleated filter and the solution is then left to crystallize at 0° C.
  • the crystallized product is filtered off with suction and dried under reduced pressure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Fuses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to polycyclic dihydrothiazoles and to their physiologically acceptable salts and physiologically functional derivatives.
Compounds of formula I,
Figure US20020058658A1-20020516-C00001
in which the radicals are as defined above, and their physiologically acceptable salts and processes for their preparation are described. The compounds are suitable, for example, as anorectics.

Description

  • This application claims priority to German Application No. 10008275.0 filed Feb. 23, 2000, the entire contents of which are hereby incorporated by reference. [0001]
    • FIELD OF THE INVENTION
  • The invention relates to polycyclic dihydrothiazoles and to their physiologically acceptable salts and physiologically functional derivatives. [0002]
    • BACKGROUND OF THE INVENTION
  • Thiazolidine derivatives having anorectic action have already been described in the prior art (Austrian Patent No. 365181). [0003]
  • The object of the invention is to provide compounds having a therapeutically useful anorectic action. The present compounds also find use in treatment of type II diabetes and obesity. [0004]
    • SUMMARY OF THE INVENTION
  • The invention relates to compounds of formula I: [0005]
    Figure US20020058658A1-20020516-C00002
  • in which [0006]
  • R1, R1′ are independently selected from H, F, Cl, Br, I, CF[0007] 3, NO2, CN, COOH, COO(C1-C6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0008] 3, OC(O)H, O—CH2—Ph, NH2, NH—CO—CH3 or N(COOCH2Ph)2;
  • SO[0009] 2—NH2, SO2NH(C1-C6)-alkyl, SO2N[(C1-C6)-alkyl]2, S—(C1-C6)-alkyl, S—(CH2)n-phenyl, SO—(C1-C6)-alkyl, SO—(CH2)n-phenyl, SO2—(C1-C6)-alkyl, SO2—(CH2)n-phenyl,
  • wherein n is 0-6 and the phenyl radical may be optionally substituted up to two times by F, Cl, Br, OH, CF[0010] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2;
  • NH[0011] 2, NH—(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH(C1-C7)-acyl, phenyl, biphenylyl, O—(CH2)n-phenyl, wherein n is 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
  • wherein any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF[0012] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, SO2—CH3, COOH, COO—(C1-C6)-alkyl or CONH2;
  • 1,2,3-triazol-5-yl, wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or [0013]
  • tetrazol-5-yl, wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl; [0014]
  • R2 is H, (C[0015] 1-C6)-alkyl, (C3-C6)-cycloalkyl, (CH2)n-phenyl, (CH2)n-thienyl, (CH2)n-pyridyl, (CH2)n-furyl, C(O)—(C1-C6)-alkyl, C(O)—(C3-C6)-cycloalkyl, C(O)—(CH2)n-phenyl, C(O)—(CH2)n-thienyl, C(O)—(CH2)n-pyridyl or C(O)—(CH2)n-furyl,
  • wherein n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl may be optionally substituted up to two times by Cl, F, CN, CF[0016] 3, (C1-C3)-alkyl, OH or O—(C1-C6)-alkyl;
  • R3 is Cl, Br, CH[0017] 2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
  • R4 is (C[0018] 1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C4-C7)-cycloalkenyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine or one hydrogen may be replaced by OH, OC(O)CH[0019] 3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
  • (CH[0020] 2)n-pyrrolidin-1-yl, (CH2)n-piperidin-1-yl, (CH2)n-morpholin-4-yl, (CH2)n-piperazin-1-yl, (CH2)n-N-4-methylpiperazin-1-yl, (CH2)n-N-4-benzylpiperazin-1-yl, (CH2)n-phthalimidoyl, where n is 1-6; (CH2)n-aryl, (CH2)n-heteroaryl,
  • wherein n is 0-6 and aryl is phenyl, biphenylyl, or 1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 1-pyrazolyl, 3- or 5-isoxazolyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2- or 5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, tetrazol-5-yl, indol-3-yl, indol-5-yl or N-methylimidazol-2-, -4- or -5-yl, and the aryl radical or the heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF[0021] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, SO—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6; (C1-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(C1-C6)-alkyl, COO(C3-C6)-cycloalkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH—CO—(C1-C6)-alkyl, NH—CO-phenyl, NH—SO2—(C1-C6)-alkyl or NH—SO2-phenyl,
  • wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C[0022] 1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2;
  • pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH[0023] 2)n-phenyl, O—(CH2)n-phenyl, S—(CH2)n-phenyl, SO2—(CH2)n-phenyl, where n is 0-3, or (CH2)n—A—R8, where n is 1-6;
  • A is 0, NH, N—(C[0024] 1-C6)-alkyl, NCHO, N(CO—CH3), S, SO or SO2;
  • R8 is (C[0025] 1-C8)-alkyl, (C3-C8)-cycloalkyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0026] 3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
  • (CH[0027] 2)m-aryl or (CH2)m-heteroaryl,
  • wherein m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF[0028] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, SO—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), (CH2)n—SO2—NH(C1-C8)-alkyl, (CH2)n—SO2—N[(C1-C8)-alkyl]2, (CH2)n—SO2—NH(C3-C8)-cycloalkyl, (CH2)n—SO2—N[(C3-C8)-cycloalkyl]2, where n is 0-6; (C1-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(C1-C6)-alkyl, COO(C3-C6)-cycloalkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH—CO—(C1-C6)-alkyl, NH—CO-phenyl, NH—SO2-phenyl,
  • where the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C[0029] 1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2,
  • NH—SO[0030] 2—(C1-C8)-alkyl, N(C1-C6)-alkyl-SO2—(C1-C8)-alkyl, pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH2)p-phenyl, O—(CH2)p-phenyl, S—(CH2)p-phenyl or SO2—(CH2)p-phenyl, wherein p is 0-3;
  • and their physiologically acceptable salts and physiologically functional derivatives. [0031]
  • The invention also relates to pharmaceutical compositions containing the compounds of formula I and pharmaceutically acceptable carriers. Also, pharmaceutical compositions containing the compounds of formula I in combination with at least one additional anorectic agents are contemplated. The invention envisages treatment of obesity via administration of compounds of formula I. Methods of treatment for type II diabetes are also contemplated. Methods of enhancing lipid metabolism can also be achieved with the compounds of formula I. [0032]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The invention is directed to polycyclic thiazole compounds which are anorectics and are useful in the treatment of type II diabetes and obesity. The compounds have general formula (I): [0033]
    Figure US20020058658A1-20020516-C00003
  • in which [0034]
  • R1, R1′ are independently selected from H, F, Cl, Br, I, CF[0035] 3, NO2, CN, COOH, COO(C1-C6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0036] 3, OC(O)H, O—CH2—Ph, NH2, NH—CO—CH3 or N(COOCH2Ph)2;
  • SO[0037] 2—NH2, SO2NH(C1-C6)-alkyl, SO2N[(C1-C6)-alkyl]2, S—(C1-C6)-alkyl, S—(CH2)n-phenyl, SO—(C1-C6)-alkyl, SO—(CH2)n-phenyl, SO2—(C1-C6)-alkyl, SO2—(CH2)n-phenyl,
  • wherein n is 0-6 and the phenyl radical may be optionally substituted up to two times by F, Cl, Br, OH, CF[0038] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2;
  • NH[0039] 2, NH—(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH(C1-C7)-acyl, phenyl, biphenylyl, O—(CH2)n-phenyl, wherein n is 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
  • wherein any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF[0040] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, SO2—CH3, COOH, COO—(C1-C6)-alkyl or CONH2;
  • 1,2,3-triazol-5-yl, wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or [0041]
  • tetrazol-5-yl, wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl; [0042]
  • R2 is H, (C[0043] 1-C6)-alkyl, (C3-C6)-cycloalkyl, (CH2)n-phenyl, (CH2)n-thienyl, (CH2)n-pyridyl, (CH2)n-furyl, C(O)—(C1-C6)-alkyl, C(O)—(C3-C6)-cycloalkyl, C(O)—(CH2)n-phenyl, C(O)—(CH2)n-thienyl, C(O)—(CH2)n-pyridyl or C(O)—(CH2)n-furyl,
  • wherein n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl may be optionally substituted up to two times by Cl, F, CN, CF[0044] 3, (C1-C3)-alkyl, OH or O—(C1-C6)-alkyl;
  • R3 is Cl, Br, CH[0045] 2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
  • R4 is (C[0046] 1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C4-C7)-cycloalkenyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine or one hydrogen may be replaced by OH, OC(O)CH[0047] 3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
  • (CH[0048] 2)n-pyrrolidin-1-yl, (CH2)n-piperidin-1-yl, (CH2)n-morpholin-4-yl, (CH2)n-piperazin-1-yl, (CH2)n-N-4-methylpiperazin-1-yl, (CH2)n-N-4-benzylpiperazin-1-yl, (CH2)n-phthalimidoyl, where n is 1-6; (CH2)n-aryl, (CH2)n-heteroaryl,
  • wherein n is 0-6 and aryl is phenyl, biphenylyl, or 1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 1-pyrazolyl, 3- or 5-isoxazolyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2- or 5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, tetrazol-5-yl, indol-3-yl, indol-5-yl or N-methylimidazol-2-, -4- or -5-yl, and the aryl radical or the heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF[0049] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, SO—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6; (C1-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(C1-C6)-alkyl, COO(C3-C6)-cycloalkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH—CO—(C1-C6)-alkyl, NH—CO-phenyl, NH—SO2—(C1-C6)-alkyl or NH—SO2-phenyl,
  • wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C[0050] 1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2;
  • pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH[0051] 2)n-phenyl, O—(CH2)n-phenyl, S—(CH2)n-phenyl, SO2—(CH2)n-phenyl, where n is 0-3, or (CH2)n—A—R8, where n is 1-6;
  • A is O, NH, N—(C[0052] 1-C6)-alkyl, NCHO, N(CO—CH3), S, SO or SO2;
  • R8 is (C[0053] 1-C8)-alkyl, (C3-C8)-cycloalkyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0054] 3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
  • (CH[0055] 2)m-aryl or (CH2)m-heteroaryl,
  • wherein m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF[0056] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, SO—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), (CH2)n—SO2—NH(C1-C8)-alkyl, (CH2)n—SO2—N[(C1-C8)-alkyl]2, (CH2)n—SO2—NH(C3-C8)-cycloalkyl, (CH2)n—SO2—N[(C3-C8)-cycloalkyl]2, where n is 0-6; (C1-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(C1-C6)-alkyl, COO(C3-C6)-cycloalkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH—CO—(C1-C6)-alkyl, NH—CO-phenyl, NH—SO2-phenyl,
  • where the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C[0057] 1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2,
  • NH—SO[0058] 2—(C1-C8)-alkyl, N(C1-C6)-alkyl-SO2—(C1-C8)-alkyl, pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH2)p-phenyl, O—(CH2)p-phenyl, S—(CH2)p-phenyl or SO2—(CH2)p-phenyl, wherein p is 0-3;
  • and their physiologically acceptable salts and physiologically functional derivatives. [0059]
  • In a preferred embodiment are compounds of Formula I wherein: [0060]
  • R1, R1′ are independently selected from H, F, Cl, Br, I, CF[0061] 3, NO2, CN, COOH, COO(C1-C6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0062] 3, OC(O)H, O—CH2—Ph, NH2, NH—CO—CH3 or N(COOCH2Ph)2;
  • SO[0063] 2—NH2, SO2NH(C1-C6)-alkyl, SO2N[(C1-C6)-alkyl]2, S—(C1-C6)-alkyl, S—(CH2)n-phenyl, SO—(C1-C6)-alkyl, SO—(CH2)n-phenyl, SO2—(C1-C6)-alkyl, SO2—(CH2)n-phenyl,
  • where n is 0-6, and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF[0064] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl or NH2;
  • NH[0065] 2, NH—(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH(C1-C7)-acyl, phenyl, biphenylyl, O—(CH2)n-phenyl, where n is 0-6, 1 - or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
  • wherein any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF[0066] 3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, SO2—CH3, COOH, COO—(C1-C6)-alkyl or CONH2;
  • 1,2,3-triazol-5-yl, wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or [0067]
  • tetrazol-5-yl, wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl; [0068]
  • R2 is H, (C[0069] 1-C6)-alkyl, (C3-C6)-cycloalkyl, (CH2)n-phenyl, (CH2)n-thienyl, (CH2)n-pyridyl, (CH2)n-furyl, C(O)—(C1-C6)-alkyl, C(O)—(C3-C6)-cycloalkyl, C(O)—(CH2)n-phenyl, C(O)—(CH2)n-thienyl, C(O)—(CH2)n-pyridyl or C(O)—(CH2)n-furyl,
  • wherein n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl can in each case be substituted up to two times by Cl, F, CN, CF[0070] 3, (C1-C3)-alkyl, OH or O—(C1-C6)-alkyl;
  • R3 is Cl, Br, CH[0071] 2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
  • R4 is (C[0072] 1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C4-C7)-cycloalkenyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0073] 3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
  • (CH[0074] 2)n-pyrrolidin-1-yl, (CH2)n-piperidin-1-yl, (CH2)n-morpholin-4-yl, (CH2)n-piperazin-1-yl, (CH2)n—N-4-methylpiperazin-1-yl, (CH2)n—N-4-benzylpiperazin-1-yl, (CH2)n-phthalimidoyl, wherein n is 1-6, (CH2)n-aryl, (CH2)n-heteroaryl,
  • wherein n is 0-6 and aryl is phenyl or 1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl, 2- or 3-thienyl and the aryl radical or heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF[0075] 3, O—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6, NH—SO2—(C1-C6)-alkyl or NH—SO2-phenyl,
  • wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C[0076] 1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2;
  • (C[0077] 1-C6)-alkyl, COOH, COO(C1-C6)-alkyl, CONH2 or (CH2)n—A—R8, wherein n is 1-6;
  • A is O, NH, (C[0078] 1-C6)-alkyl or SO2;
  • R8 is (C[0079] 1-C8)-alkyl, (C3-C8)-cycloalkyl,
  • wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH[0080] 3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
  • (CH[0081] 2)m-aryl or (CH2)n-heteroaryl,
  • wherein m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl, and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF[0082] 3, O—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6, NH—SO2—(C1-C6)-alkyl, NH—SO2-phenyl,
  • wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C[0083] 1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2, where n is 0-6;
  • COOH, COO(C[0084] 1-C6)-alkyl, or CONH2;
  • and their physiologically acceptable salts and physiologically functional derivatives. [0085]
  • In a particularly preferred embodiment are compounds of Formula I wherein: [0086]
  • R1, R1′ are independently selected from H, F, Cl, Br, —OH, O—(C[0087] 1-C6)-alkyl or (C1-C6)-alkyl,
  • wherein one of the hydrogens of the alkyl radicals may be replaced by OH; [0088]
  • R2 is H, (C[0089] 1-C6)-alkyl or C(O)—(C1-C6)-alkyl;
  • R3 is Cl, Br, CH[0090] 2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
  • R4 is (C[0091] 1-C4)-alkyl, (C3-C6)-cycloalkyl,
  • wherein one of the hydrogens of the alkyl radicals may be replaced by OH; [0092]
  • (CH[0093] 2)n-aryl, (CH2)n-heteroaryl,
  • wherein n is 0-6 and aryl may be phenyl or1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl or 2- or 3-thienyl, and the aryl radical or heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF[0094] 3, O—(C1-C6)-alkyl, SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, wherein n is 0-6, (C1-C6)-alkyl, COOH, COO(C1-C6)-alkyl or CONH2; or
  • (CH[0095] 2)n—A—R8, wherein n is 1-6;
  • A is O or SO[0096] 2;
  • R8 is (C[0097] 1-C8)-alkyl, (C3-C8)-cycloalkyl,
  • wherein one of the hydrogens of the alkyl radicals may be replaced by OH; [0098]
  • (CH[0099] 2)m-aryl or (CH2)n-heteroaryl,
  • wherein m is 0-6 and aryl is phenyl and heteroayl is thienyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF[0100] 3, O—(C1-C6)-alkyl, SO2—(C1-C6)-alkyl, SO2—NH2, COOH, COO(C1-C6)-alkyl or CONH2;
  • and their physiologically acceptable salts. [0101]
  • The invention relates to compounds of formula I, in the form of their racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof. [0102]
  • The alkyl, alkenyl and alkynyl radicals in the substituents R1, R1′, R2, R3, R4, R8 and A may be either straight-chain or branched. [0103]
  • Pharmaceutically acceptable salts are particularly suitable for medicinal applications as compared with the starting materials or base compounds, due to their higher water solubility. These salts have a pharmaceutically acceptable anion or cation. Suitable pharmaceutically acceptable acid addition salts of the compounds according to the invention are salts of inorganic acids, including but not limited to, hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfonic acid and sulfuric acid, and salts of organic acids, such as, for example, acetic acid, benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glycolic acid, isethionic acid, lactic acid, lactobionic acid, maleic acid, malic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid, tartaric acid and trifluoroacetic acid. For medicinal purposes, the chlorine salt is one of the preferred. Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium salts and potassium salts) and alkaline earth metal salts (such as magnesium salts and calcium salts). [0104]
  • Salts having a pharmaceutically unacceptable anion are likewise included in the scope of the invention as useful intermediates for the production or purification of pharmaceutically acceptable salts and/or for use in non-therapeutic, for example in-vitro, applications. In addition, pharmaceutically unacceptable anions may be useful for the separation of enantiomers and diasteromers. [0105]
  • The term “physiologically functional derivative” as used herein relates to any physiologically acceptable derivative of a compound of formula I according to the invention, for example an ester, which on administration to a mammal, such as, for example, man, is able (directly or indirectly) to form a compound of formula I or an active metabolite thereof. [0106]
  • The physiologically functional derivatives also include prodrugs of the compounds according to the invention. Such prodrugs may be metabolized in vivo to a compound according to the invention. These prodrugs may themselves be active or inactive. [0107]
  • The compounds according to the invention may also be present in various polymorphic forms, for example as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds according to the invention are included in the scope of the invention and are a further aspect of the invention. [0108]
  • Hereinbelow, all references to “compound(s) according to formula (I)” refer to a compound/compounds of formula (I) as described above, and to their salts, solvates and physiologically functional derivatives as described herein. [0109]
  • The amount of a compound according to formula (I) which is necessary to achieve the desired biological effect depends upon a number of factors, for example, the specific compound selected, the intended use, the manner of administration and the clinical condition of the patient. In general, the daily dose is in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of bodyweight, for example 3-10 mg/kg/day. An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg, which may be suitably administered as an infusion of 10 ng to 100 ng per kilogram per minute. Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter. Individual doses may contain, for example, from 1 mg to 10 g of the active compound. Thus, ampoules for injections may contain, for example, from 1 mg to 100 mg, and orally administrable individual dose formulations, such as, for example, tablets or capsules, may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically acceptable salts, the abovementioned weight details relate to the weight of the dihydrothiazolium ion derived from the salt. For the prophylaxis or therapy of the abovementioned conditions, the compounds according to formula (I) may be used themselves as the compound, but they are preferably present in the form of a pharmaceutical composition with a tolerable excipient. The excipient is a pharmaceutically acceptable excipient, this means that it is compatible with the other constituents of the composition and is not harmful to the patient's health. The excipient may be a solid or a liquid or both and is preferably formulated with the compound as an individual dose, for example as a tablet which may contain from 0.05% to 95% by weight of the active compound. Further pharmaceutically active substances may also be present, including further compounds according to formula (I). The pharmaceutical compositions according to the invention may be prepared by one of the known pharmaceutical methods, which essentially consist in mixing the constituents with pharmacologically acceptable excipients and/or auxiliaries. [0110]
  • Pharmaceutical compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (e.g. sublingual) and parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable manner of administration in each individual case is dependent on the nature and severity of the condition to be treated and on the nature of the compound according to formula (I) used in each case. Sugar-coated formulations and sugar-coated delayed release formulations are also included in the scope of the invention. Acid-resistant and enteric formulations are preferred. Suitable enteric coatings include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and anionic polymers of methacrylic acid and methyl methacrylate. [0111]
  • Suitable pharmaceutical compounds for oral administration may be present in separate units, such as, for example, capsules, cachets, lozenges or tablets which in each case contain a certain amount of the compound according to formula (I); as powders or granules; as solution or suspension in an aqueous or nonaqueous liquid; or as an oil-in-water or water-in-oil emulsion. As already mentioned, these compositions may be prepared by any suitable pharmaceutical method which includes a step in which the active compound and the excipient (which may consist of one or more additional constituents) are brought into contact. In general, the compositions are prepared by uniform and homogeneous mixing of the active compound with a liquid and/or finely divided solid excipient, after which the product is shaped, if necessary. Thus a tablet, for example, may be prepared by pressing or shaping a powder or granules of the compound, if appropriate, with one or more additional constituents. Pressed tablets may be prepared by tableting the compound in free-flowing form, such as, for example, in a powder or granules, if appropriate mixed with a binder, lubricant, inert diluent and/or one (a number of) surface-active/dispersing agent(s) in a suitable machine. Shaped tablets may be prepared by shaping the pulverulent compound, moistened with an inert liquid diluent, in a suitable machine. [0112]
  • Pharmaceutical compositions which are suitable for peroral (sublingual) administration include lozenges which contain a compound according to formula (I) with a flavoring, customarily sucrose and gum arabic or tragacanth, and pastilles which include the compound in an inert base such as gelatin and glycerol or sucrose and gum arabic. [0113]
  • Suitable pharmaceutical compositions for parenteral administration preferably include sterile aqueous preparations of a compound according to formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also take place subcutaneously, intramuscularly or intradermally as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the obtained solution sterile and isotonic with the blood. Injectable compositions according to the invention in general contain from 0.1 to 5% by weight of the active compound. [0114]
  • Suitable pharmaceutical compositions for rectal administration are preferably present as individual dose suppositories. These may be prepared by mixing a compound according to formula (I) with one or more conventional solid excipients, for example cocoa butter, and shaping the resulting mixture. [0115]
  • Suitable pharmaceutical compositions for topical application to the skin are preferably present as ointment, cream, lotion, paste, spray, aerosol or oil. Excipients which may be used are petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances. The active compound is in general present in a concentration of from 0.1 to 15%, for example of from 0.5 to 2%, by weight of the composition. [0116]
  • Transdermal administration is also possible. Suitable pharmaceutical compositions for transdermal administration may be present as individual patches which are suitable for long-term close contact with the epidermis of the patient. Such patches suitably contain the active compound in an optionally buffered aqueous solution, dissolved and/or dispersed in an adhesive or dispersed in a polymer. A suitable active compound concentration is from about 1% to 35%, preferably from about 3% to 15%. As a particular possibility, the active compound may be released by electrotransport or iontophoresis, as described, for example, in Pharmaceutical Research, 2(6): 318 (1986). [0117]
  • The invention furthermore relates to a process for preparing the compounds of formula I, which comprises reaction steps according to the scheme set forth below: [0118]
    Figure US20020058658A1-20020516-C00004
  • in which R1 and R1′ are as defined above, are reacted with a compound of formula Z—CH[0119] 2—COOR, in which Z is, for example, halogen or another appropriate leaving group and R is, for example, methyl or another alkyl moiety to yield a compound of formula III in which R3 is —CH2—COOR.
  • The compounds of formula III are reacted further with a halogen, for example bromine, to give compounds of formula IV in which R1 and R1 ′ are as defined above and R3 is, for example, —CH[0120] 2—COOR.
  • Compounds of formula IV may then be converted to the thioamides of Formula VI [0121]
    Figure US20020058658A1-20020516-C00005
  • in which R4 is as defined above, to yield compounds of Formula I. Compounds of Formula I in which R3 is chlorine or bromine may be prepared by reacting compounds of Formula V with a halogenating agent, such as, for example, N-chlorosuccinimide or N-bromosuccinimide. [0122]
  • The compounds of Formula I may also be present as salts with acids. Suitable inorganic acids are, for example: [0123]
  • Hydrohalic acids, such as hydrochloric acid and hydrobromic acid, and also sulfuric acid, phosphoric acid and amidosulfonic acid. [0124]
  • Organic acids which may be useful include, but are not limited to: formic acid, acetic acid, benzoic acid, p-toluenesulfonic acid, benzenesulfonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, citric acid, L-ascorbic acid, salicylic acid, isethionic acid, methanesulfonic acid, trifluoromethanesulfonic acid, 1,2-benzisothiazol-3(2H)-one, 6-methyl-1,2,3-oxathiazin-4(3H)-one 2,2-dioxide. [0125]
  • In the reaction scheme described above, it is advantageous to react the compounds of Formula IV with the thioamides of Formula VI in a molar ratio of from 1:1 to 1:1.5. The reaction is carried out in an inert solvent, for example, polar organic solvents, such as dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, dioxane, tetrahydrofuran, acetonitrile, nitromethane or diethylene glycol dimethyl ether. Particularly preferred solvents, however, include but are not limited to methyl acetate and ethyl acetate, short-chain alcohols, such as methanol, ethanol, propanol, isopropanol, and lower dialkyl ketones, such as, for example, acetone, butan-2-one or hexan-2-one. Mixtures of the reaction media mentioned may also be used; and mixtures of the solvents mentioned with solvents which, taken per se, are less suitable, such as, for example, mixtures of methanol with benzene, ethanol with toluene, methanol with diethyl ether or with tert-butyl methyl ether, ethanol with carbon tetrachloride, acetone with chloroform, dichloromethane or 1,2- dichloroethane, may also be used, where the more polar solvent in each case should be used in an excess. The reactants may be suspended or dissolved in the respective reaction medium. In principle, the reactants may also be reacted in the absence of a solvent, in particular if the respective thioamide has a melting point which is as low as possible. The reaction, which proceeds in a slightly exothermic manner, may be carried out between −10° C. and 150° C., preferably between 30° C. and 100° C. A temperature range between 50° C. and 90° C. has generally been found to be favorable. [0126]
  • The reaction time is largely dependent on the reaction temperature and is between 2 minutes and 3 days at relatively high and relatively low temperatures, respectively. In the favorable temperature range, the reaction time is generally between 5 minutes and 48 hours. [0127]
  • In the course of the reaction, the compounds of Formula I have been shown to form a poorly soluble deposit in the form of their acid addition salts, addition of a suitable precipitating agent is subsequently added. Those precipitating used are, for example, hydrocarbons such as benzene, toluene, cyclohexane or heptane or carbon tetrachloride; in particular, alkyl acetates, such as ethyl acetate or n-butyl acetate, or dialkyl ethers, such as diethyl ether, diisopropyl ether, di-n-butyl ether or tert-butyl methyl ether prove particularly suitable. If the reaction mixture remains in solution after the end of the reaction, the salts of the compounds I may be precipitated using one of the precipitating agents mentioned, if appropriate after concentration of the reaction solution. Furthermore, the solution of the reaction mixture may also be advantageously filtered into the solution of one of the precipitating agents mentioned, with stirring. Since the reaction of the compounds of formula IV with the thioamides of formula VI proceeds almost quantitavely, the crude products obtained are mostly already analytically pure. Work-up of the reaction mixture may also be carried out such that the reaction mixture is rendered alkaline by addition of an organic base, such as, for example, triethylamine or diisobutylamine or ammonia or morpholine or piperidine or 1,8-diazabicyclo[5.4.0]undec-7-ene, and the crude reaction product is purified chromatographically, for example on a silica gel column, after concentration. Suitable eluents for the chromatography are, for example, mixtures of ethyl acetate with methanol, mixtures of dichloromethane with methanol, mixtures of toluene with methanol or ethyl acetate or mixtures of ethyl acetate with hydrocarbons such as heptane. If the purification of the crude product is carried out in the manner previously described, an acid addition product of formula I may be obtained from the pure base of formula I thus obtained by dissolving or suspending the base in an organic protic solvent, such as methanol, ethanol, propanol or isopropanol, or in an organic aprotic solvent, such as ethyl acetate, diethyl ether, diisopropyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, acetone or butan-2-one, and then treating this mixture with an at least equimolar amount of an inorganic acid such as, for example, hydrochloric acid, dissolved in an inert solvent such as, for example, diethyl ether or ethanol, or another of the inorganic or organic acids mentioned further above. [0128]
  • The compounds of formula I may be recrystallized from an inert suitable solvent such as, for example, acetone, butan-2-one, acetonitrile or nitromethane. However, particularly advantageous is reprecipitation from a solvent such as, for example, dimethylformamide, dimethylacetamide, nitromethane, acetonitrile, preferably methanol or ethanol. [0129]
  • The reaction of the compounds of formula IV with the thioamides of formula VI may also be carried out such that an at least equimolar amount of a base, such as, for example, triethylamine, is added to the reaction mixture and the resulting compounds of Formula I are then optionally converted into their acid addition products. [0130]
  • The acid addition products of Formula I may be reacted to yield the compounds of formula I (free base) by treatment with a base. Suitable bases are, for example, solutions of inorganic hydroxides, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide or barium hydroxide, carbonates or hydrogen carbonates, such as sodium carbonate or potassium carbonate, sodium hydrogen carbonate or potassium hydrogen carbonate, ammonia and amines, such as triethylamine, diisopropylamine, dicyclohexylamine, piperidine, morpholine, methyldicyclohexylamine. [0131]
  • Thioamides of formula VI are either commercially available or may be obtained, for example, by reaction of the corresponding carboxamide V with phosphorus pentasulfide in pyridine (R. N. Hurd, G. Delameter, Chem. Rev. 61, 45 (1961)), or with Lawesson's reagent in toluene, pyridine, hexamethylphosphoric triamide [Scheibye, Pedersen and Lawesson: Bull. Soc. Chim. Belges 87, 229 (1978)], preferably in a mixture of tetrahydrofuran with 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,3-dimethyl-2-imidazolidinone. Hydroxyl, amino or additional carbonyl functions are in this case protected using a removable protective function, such as, for example, a benzyl, tert-butyloxycarbonyl or benzyloxycarbonyl radical, or converted into an optionally cyclic acetal. Methods for this are described, for example, in Th. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Second Edition, 1991, John Wiley & Sons, New York. [0132]
  • Thioamides of Formula VI may also be obtained by reacting nitriles of formula VII [0133]
  • N≡C—R4
  • Formula VII [0134]
  • with hydrogen sulfide (Houben-Weyl IX, 762) or thioacetamide (E. C. Taylor, J. A. Zoltewicz, J. Am. Chem. Soc. 82, 2656 (1960)) or O,O-diethyl dithiophosphoric acid. The reactions with hydrogen sulfide are preferably carried out in an organic solvent, such as methanol or ethanol, those with thioacetamide in a solvent such as dimethylformamide with addition of hydrochloric acid, and those with O,O-diethyl dithiophosphoric acid in a solvent such as ethyl acetate under acidic, e.g. HCl, conditions at room temperature or with warming. [0135]
  • The examples given below serve to illustrate the invention, but without restricting it. The measured melting or decomposition points (m.p.) were not corrected and are generally dependent on the heating rate. [0136]
    TABLE 1
    Examples
    Figure US20020058658A1-20020516-C00006
    Example R1; R1′ R2 R3 R4 Salt m.p. [° C.]
    1 6-Cl; H H Br Phenyl — 148
    2 6-Cl; H H Cl Phenyl — 88
  • The compounds of formula I are distinguished by favorable effects on lipid metabolism; in particular, they are suitable as anorectics. Other favorable effects on lipid metabolism include lowering cholesterol or low density lipoproteins (LDL) and increasing high density lipoproteins (HDL). The compounds may be employed on their own or in combination with other anorectically active compounds. Such further anorectically active compounds are mentioned, for example, in the Rote Liste, chapter 01 under slimming preparations/anorectics. Examples include, but are not limited to, DECORPA© (from Pierre Fabre Pharma, common name, sterculia), XENICAL© (from Roche, common name orlistat), ANTIADIPOSITUM X-112S (from Haenseler, common name, D-norpseudoephedrin-HCl), FASUPOND© (from Eu Rho Arzneil, common name, D-norpseudoephedrin-HCl), MIRAPRONT© N (from Mack, Illert., common name, D-norpseudoephedrin-Poly(styrol, divinylbenzol) sulfonate), REGENON© l-retard (from Temmler Pharma, common name, Amfepramon-HCl), RONDIMEN© (from ASTA Medica AWD, common name, Mefenorex-HCl), TENUATE(© Retard (from Artegodan, common name, Amfepramon-HCl), Vita-Schlanktropfen Schuck (from Schuck, common name, D-norpseudoephedrin-HCl), VENCIPONO© N (from Artesan, common name, Ephedrin-HCl), CEFAMADAR© (from Cefak, common name Madar D4), and Helianthus tuberosus (Plantina). The compounds are suitable for the prophylaxis and in particular for the treatment of obesity. The compounds are furthermore suitable for the prophylaxis and in particular for the treatment of type II diabetes. [0137]
  • The efficacy of the compounds was tested as follows: [0138]
  • Biological test model: [0139]
  • The anorectic action was tested on female NMRI mice. After withdrawal of food for 24 hours, the test preparation of the invention was administered via a stomach tube. Kept individually and with free access to drinking water, the animals were offered evaporated milk 30 minutes after the administration of the preparation. The consumption of evaporated milk was determined every half-hour for 7 hours and the general condition of the animals was observed. The measured milk consumption was compared with that of untreated control animals. [0140]
    TABLE 2
    Anorectic action, measured as reduction of the cumulated milk
    consumption of treated animals compared to untreated animals.
    Compound/Example
    Figure US20020058658A1-20020516-C00007
         		Oral dose [mg/kg] Number of animals/ cumulated milk consumption of the treated animals N/[ml] Number of animals/ cumulated milk consumption of the untreated control animals N/[ml] Reduction of the cumulated milk consumption in % of the control
    Example 1 50 5/0.64 5/3.50 82
  • The data from the above table indicates that the compounds of Formula I exhibit very good anorectic action. [0141]
  • The preparation of some examples is described in detail below; the other compounds of formula I were obtained in a similar manner: [0142]
    • EXAMPLE 1 (Compound 1) 8a-Bromo-6-chloro-2-phenyl-8,8a-dihydroindeno[1,2-d]thiazol-3a-ol
  • a) 2-Bromo-5-chloroindan-1-one: [0143]
  • At room temperature, 10 g (0.06 mol) of 5-chloroindan-1-one is dissolved with stirring in 120 ml of glacial acetic acid. 0.05 ml of a 48% strength solution of HBr in water and then 3.074 ml (0.06 mol) of bromine, dissolved in 25 ml of glacial acetic acid, are added dropwise. After 2 h of stirring at room temperature, the reaction reached completion ( as determined by thin layer chromatography (TLC). The solution of the crude product is slowly added dropwise with stirring to 300 ml of ice-water. The precipitated crude product is filtered off with suction and washed thoroughly with water. The moist residue is removed from the filter using ethyl acetate, and the phases of the filtrate are separated. The organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue is dissolved in 120 ml of hot n-heptane; the hot solution is filtered through a pleated filter and the solution is then left to crystallize at 0° C. The crystallized product is filtered off with suction and dried under reduced pressure. [0144]
  • M.p.: 94-96° C. [0145]
  • b) 6-Chloro-2-phenyl-8,8a-dihydroindeno[1,2-d]thiazol-3a-ol [0146]
  • At room temperature, 1.0 g of 2-bromo-5-chloroindan-1-one is dissolved in 20 ml of dry acetone and admixed with 620 mg of thiobenzamide. The mixture is stirred at room temperature for 6 h, the crystallized hydrobromide product is filtered off with suction and the residue is washed with acetone and dried under reduced pressure. The free base is obtained by introducing the salt into a mixture of 30 ml of ethyl acetate and 20 ml of saturated sodium bicarbonate solution and stirring for 20 min. The organic phase is separated off, washed with saturated sodium chloride solution and dried over magnesium sulfate. The mixture is filtered and the filtrate is concentrated under reduced pressure. This gives 6-chloro-2-phenyl-8,8a-dihydroindeno[1,2-d]thiazol-3a-ol having a melting point of 164-165° C. [0147]
  • c) 8a-Bromo-6-chloro-2-phenyl-8,8a-dihydroindeno[1,2-d]thiazol-3a-ol: [0148]
  • 1.51 g of the compound of Example 1b and 0.89 g of N-bromosuccinimide are dissolved in 20 ml of carbon tetrachloride and admixed with 50 mg of benzoyl peroxide, and then the mixture is stirred under reflux for 3 h. After cooling, the reaction solution is extracted twice with 20 ml of water and the organic phase is dried over magnesium sulfate, filtered and concentrated under reduced pressure. Chromatographic purification on silica gel using the mobile phase dichloromethane gives 8a-bromo-6-chloro-2-phenyl-8,8a-dihydroindeno[1,2-d]thiazol-3a-ol having a melting point of 148° C. [0149]

Claims (31)

What is claimed is:
1. A compound of formula I,
Figure US20020058658A1-20020516-C00008
in which
R1, R1′ are independently selected from H, F, Cl, Br, I, CF3, NO2, CN, COOH, COO(C1-C6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl,
wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH3, OC(O)H, O—CH2—Ph, NH2, NH—CO—CH3 or N(COOCH2Ph)2;
SO2—NH2, SO2NH(C1-C6)-alkyl, SO2N[(C1-C6)-alkyl]2, S—(C1-C6)-alkyl, S—(CH2)n-phenyl, SO—(C1-C6)-alkyl, SO—(CH2)n-phenyl, SO2—(C1-C6)-alkyl, SO2—(CH2)n-phenyl,
wherein n is 0-6 and the phenyl radical may be optionally substituted up to two times by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2;
NH2, NH—(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH(C1-C7)-acyl, phenyl, biphenylyl, O—(CH2)n-phenyl, wherein n is 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
wherein any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, SO2—CH3, COOH, COO—(C1-C6)-alkyl or CONH2;
1,2,3-triazol-5-yl, wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or
tetrazol-5-yl, wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl;
R2 is H, (C1-C6)-alkyl, (C3-C6)-cycloalkyl, (CH2)n-phenyl, (CH2)n-thienyl, (CH2)n-pyridyl, (CH2)n-furyl, C(O)—(C1-C6)-alkyl, C(O)—(C3-C6)-cycloalkyl, C(O)—(CH2)n-phenyl, C(O)—(CH2)n-thienyl, C(O)—(CH2)n-pyridyl or C(O)—(CH2)n-furyl,
wherein n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl may be optionally substituted up to two times by Cl, F, CN, CF3, (C1-C3)-alkyl, OH or O—(C1-C6)-alkyl;
R3 is Cl, Br, CH2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
R4 is (C1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C4-C7)-cycloalkenyl,
wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine or one hydrogen may be replaced by OH, OC(O)CH3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
(CH2)n-pyrrolidin-1-yl, (CH2)n-piperidin-1-yl, (CH2)n-morpholin-4-yl, (CH2)n-piperazin-1-yl, (CH2)n—N-4-methylpiperazin-1-yl, (CH2)n—N-4-benzylpiperazin-1-yl, (CH2)n-phthalimidoyl, where n is 1-6; (CH2)n-aryl, (CH2)n-heteroaryl,
wherein n is 0-6 and aryl is phenyl, biphenylyl, or 1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 1-pyrazolyl, 3- or 5-isoxazolyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2- or 5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, tetrazol-5-yl, indol-3-yl, indol-5-yl or N-methylimidazol-2-, -4- or -5-yl, and the aryl radical or the heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, SO—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6; (C1-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(C1-C6)-alkyl, COO(C3-C6)-cycloalkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH—CO—(C1-C6)-alkyl, NH—CO-phenyl, NH—SO2-(C1-C6)-alkyl or NH—SO2-phenyl,
wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2;
pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH2)n-phenyl, O—(CH2)n-phenyl, S—(CH2)n-phenyl, SO2—(CH2)n-phenyl, where n is 0-3, or (CH2)n—A—R8, where n is 1-6;
A is O, NH, N—(C1-C6)-alkyl, NCHO, N(CO—CH3), S, SO or SO2;
R8 is (C1-C8)-alkyl, (C3-C8)-cycloalkyl,
wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
(CH2)m-aryl or (CH2)m-heteroaryl,
wherein m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, S—(C1-C6)-alkyl, SO—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), (CH2)n—SO2—NH(C1-C8)-alkyl, (CH2)n—SO2—N[(C1-C8)-alkyl]2, (CH2)n—SO2—NH(C3-C8)-cycloalkyl, (CH2)n—SO2—N[(C3-C8)-cycloalkyl]2, where n is 0-6; (C1-C6)-alkyl, (C3-C6)-cycloalkyl, COOH, COO(C1-C6)-alkyl, COO(C3-C6)-cycloalkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, CONH(C3-C6)-cycloalkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH—CO—(C1-C6)-alkyl, NH—CO-phenyl, NH—SO2-phenyl,
where the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2,
NH—SO2—(C1-C8)-alkyl, N(C1-C6)-alkyl-SO2—(C1-C8)-alkyl, pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, (CH2)p-phenyl, O—(CH2)p-phenyl, S—(CH2)p-phenyl or SO2—(CH2)p-phenyl, wherein p is 0-3;
and their physiologically acceptable salts and physiologically functional derivatives.
2. The compound of claim 1, wherein:
R1, R1′ are independently selected from H, F, Cl, Br, I, CF3, NO2, CN, COOH, COO(C1-C6)-alkyl, CONH2, CONH(C1-C6)-alkyl, CON[(C1-C6)-alkyl]2, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O—(C1-C6)-alkyl,
wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH3, OC(O)H, O—CH2—Ph, NH2, NH—CO—CH3 or N(COOCH2Ph)2;
SO2—NH2, SO2NH(C1-C6)-alkyl, SO2N[(C1-C6)-alkyl]2, S—(C1-C6)-alkyl, S—(CH2)n-phenyl, SO—(C1-C6)-alkyl, SO—(CH2)n-phenyl, SO2—(C1-C6)-alkyl, SO2—(CH2)n-phenyl,
where n is 0-6, and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl or NH2;
NH2, NH—(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, NH(C1-C7)-acyl, phenyl, biphenylyl, O—(CH2)n-phenyl, where n is 0-6, 1- or 2-naphthyl, 2-, 3- or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl,
wherein any of the phenyl, biphenylyl, naphthyl, pyridyl, furanyl or thienyl rings may be optionally substituted one to 3 times by F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O—(C1-C6)-alkyl, (C1-C6)-alkyl, NH2, NH(C1-C6)-alkyl, N[(C1-C6)-alkyl]2, SO2—CH3, COOH, COO—(C1-C6)-alkyl or CONH2;
1,2,3-triazol-5-yl, wherein the triazole ring may be substituted in the 1-, 2- or 3-position by methyl or benzyl; or
tetrazol-5-yl, wherein the tetrazole ring may be substituted in the 1- or 2-position by methyl or benzyl;
R2 is H, (C1-C6)-alkyl, (C3-C6)-cycloalkyl, (CH2)n-phenyl, (CH2)n-thienyl, (CH2)n-pyridyl, (CH2)n-furyl, C(O)—(C1-C6)-alkyl, C(O)—(C3-C6)-cycloalkyl, C(O)—(CH2)n-phenyl, C(O)—(CH2)n-thienyl, C(O)—(CH2)n-pyridyl or C(O)—(CH2)n-furyl,
wherein n is 0-5 and in which any of phenyl, thienyl, pyridyl or furyl can in each case be substituted up to two times by Cl, F, CN, CF3, (C1-C3)-alkyl, OH or O—(C1-C6)-alkyl;
R3 is Cl, Br, CH2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
R4 is (C1-C8)-alkyl, (C3-C7)-cycloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C4-C7)-cycloalkenyl,
wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
(CH2)n-pyrrolidin-1-yl, (CH2)n-piperidin-1-yl, (CH2)n-morpholin-4-yl, (CH2)n-piperazin-1-yl, (CH2)n—N-4-methylpiperazin-1-yl, (CH2)n—N-4-benzylpiperazin-1-yl, (CH2)n-phthalimidoyl, wherein n is 1-6, (CH2)n-aryl, (CH2)n-heteroaryl,
wherein n is 0-6 and aryl is phenyl or 1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl, 2- or 3-thienyl and the aryl radical or heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF3, O—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6, NH—SO2—(C1-C6)-alkyl or NH—SO2-phenyl,
wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2;
(C1-C6)-alkyl, COOH, COO(C1-C6)-alkyl, CONH2 or (CH2)n—A—R8, wherein n is 1-6;
A is O, NH, (C1-C6)-alkyl or SO2;
R8 is (C1-C8)-alkyl, (C3-C8)-cycloalkyl,
wherein one or more of the hydrogens of the alkyl radicals may be replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH3, OC(O)H, O—CH2—Ph or O—(C1-C4)-alkyl;
(CH2)m-aryl or (CH2)n-heteroaryl,
wherein m is 0-6 and aryl is phenyl and heteroaryl is thienyl or pyridyl, and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF3, O—(C1-C6)-alkyl, (CH2)n—SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, (CH2)n—SO2—N(═CH—N(CH3)2), wherein n is 0-6, NH—SO2—(C1-C6)-alkyl, NH—SO2-phenyl,
wherein the phenyl ring may be substituted up to two times by F, Cl, CN, OH, (C1-C6)-alkyl, O—(C1-C6)-alkyl, CF3, COOH, COO(C1-C6)-alkyl or CONH2, where n is 0-6;
COOH, COO(C1-C6)-alkyl, or CONH2;
and their physiologically acceptable salts and physiologically functional derivatives.
3. The compound of claim 1, wherein:
R1, R1′ are independently selected from H, F, Cl, Br, —OH, O—(C1-C6)-alkyl or (C1-C6)-alkyl,
wherein one of the hydrogens of the alkyl radicals may be replaced by OH;
R2 is H, (C1-C6)-alkyl or C(O)—(C1-C6)-alkyl;
R3 is Cl, Br, CH2—COO(C1-C6)-alkyl, CH2—COOH or CH2—CONH2;
R4 is (C1-C4)-alkyl, (C3-C6)-cycloalkyl,
wherein one of the hydrogens of the alkyl radicals may be replaced by OH;
(CH2)n-aryl, (CH2)n-heteroaryl,
wherein n is 0-6 and aryl may be phenyl or1- or 2-naphthyl and heteroaryl is 2-, 3- or 4-pyridyl or 2- or 3-thienyl, and the aryl radical or heteroaryl radical may be substituted up to two times by F, Cl, Br, OH, CF3, O—(C1-C6)-alkyl, SO2—(C1-C6)-alkyl, (CH2)n—SO2—NH2, wherein n is 0-6, (C1-C6)-alkyl, COOH, COO(C1-C6)-alkyl or CONH2; or
(CH2)n—A—R8, wherein n is 1-6;
A is O or SO2;
R8 is (C1-C8)-alkyl, (C3-C8)-cycloalkyl,
wherein one of the hydrogens of the alkyl radicals may be replaced by OH;
(CH2)m-aryl or (CH2)n-heteroaryl,
wherein m is 0-6 and aryl is phenyl and heteroayl is thienyl and the aryl or heteroaryl moiety may be substituted up to two times by F, Cl, Br, OH, CF3, O—(C1-C6)-alkyl, SO2—(C1-C6)-alkyl, SO2—NH2, COOH, COO(C1-C6)-alkyl or CONH2;
and their physiologically acceptable salts.
4. A pharmaceutical composition, comprising one or more compounds as claimed in claim 1.
5. A pharmaceutical composition, comprising one or more compounds as claimed in claim 2.
6. A pharmaceutical composition, comprising one or more compounds as claimed in claim 3.
7. A pharmaceutical composition comprising one or more compounds as claimed in claim 1, and further comprising one or more anorectic active ingredients.
8. A pharmaceutical composition comprising one or more compounds as claimed in claim 2, and further comprising one or more anorectic active ingredients.
9. A pharmaceutical composition comprising one or more compounds as claimed in claim 3, and further comprising one or more anorectic active ingredients.
10. A method for the prophylaxis or treatment of obesity comprising administering to a patient in need thereof one or more compounds as claimed in claim 1.
11. The method of claim 10, further comprising administering an additional anorectic active agent.
12. A method for the prophylaxis or treatment of obesity comprising administering to a patient in need thereof one or more compounds as claimed in claim 2.
13. The method of claim 12, further comprising administering an additional anorectic active agent.
14. A method for the prophylaxis or treatment of obesity comprising administering to a patient in need thereof one or more compounds as claimed in claim 3.
15. The method of claim 14, further comprising administering an additional anorectic active agent.
16. A method for the prophylaxis or treatment of type II diabetes comprising administering to a patient in need thereof one or more compounds as claimed in claim 1.
17. The method of claim 16, further comprising administering an additional anorectic active agent.
18. A method for the prophylaxis or treatment of type II diabetes comprising administering to a patient in need thereof one or more compounds as claimed in claim 2.
19. The method of claim 18, further comprising administering an additional anorectic active agent.
20. A method for the prophylaxis or treatment of type II diabetes comprising administering to a patient in need thereof one or more compounds as claimed in claim 3.
21. The method of claim 20, further comprising administering an additional anorectic active agent.
22. A method for enhancing lipid metabolism comprising administering to a patient in need thereof one or more compounds as claimed in claim 1.
23. The method of claim 22, further comprising administering an additional anorectic active agent.
24. A method for enhancing lipid metabolism comprising administering to a patient in need thereof one or more compounds as claimed in claim 2.
25. The method of claim 24, further comprising administering an additional anorectic active agent.
26. A method for enhancing lipid metabolism comprising administering to a patient in need thereof one or more compounds as claimed in claim 3.
27. The method of claim 26, further comprising administering an additional anorectic active agent.
28. A process for preparing a pharmaceutical composition comprising one or more of the compounds as claimed in claim 1, which comprises mixing the active compound with a pharmaceutically suitable excipient and forming a composition suitable for administration.
29. A process for preparing a pharmaceutical composition comprising one or more of the compounds as claimed in claim 2, which comprises mixing the active compound with a pharmaceutically suitable excipient and forming a composition suitable for administration.
30. A process for preparing a pharmaceutical composition comprising one or more of the compounds as claimed in claim 3, which comprises mixing the active compound with a pharmaceutically suitable excipient and forming a composition suitable for administration.
31. A process for preparing compounds as claimed in claim 1, which comprises reacting, according to the equation below,
Figure US20020058658A1-20020516-C00009
either a compound of formula IV in which R1 and R1′ are as defined for formula I and Hal is a halogen atom and R is an alkyl radical, with a compound VI in which R4 is as defined for formula I, or a compound V in which R1, R1′, R2 and R4 are as defined for formula I, with a halogenating agent, such as, for example, N-chlorosuccinimide or N-bromosuccinimide, to give compounds of formula I.
US09/790,911 2000-02-23 2001-02-23 8,8A-dihydroindeno[1,2-D] thiazole derivatives which are substituted in the 8A-position; processes for their preparation and their use as medicaments Expired - Lifetime US6403624B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10008275 2000-02-23
DE10008275 2000-02-23
DE10008275.0 2000-02-23

Publications (2)

Publication Number Publication Date
US20020058658A1 true US20020058658A1 (en) 2002-05-16
US6403624B1 US6403624B1 (en) 2002-06-11

Family

ID=7631989

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/790,911 Expired - Lifetime US6403624B1 (en) 2000-02-23 2001-02-23 8,8A-dihydroindeno[1,2-D] thiazole derivatives which are substituted in the 8A-position; processes for their preparation and their use as medicaments

Country Status (27)

Country Link
US (1) US6403624B1 (en)
EP (1) EP1259498B1 (en)
JP (1) JP4898052B2 (en)
KR (1) KR20020079891A (en)
CN (1) CN1195747C (en)
AT (1) ATE283265T1 (en)
AU (1) AU781003B2 (en)
BR (1) BR0108605A (en)
CA (1) CA2400698A1 (en)
CZ (1) CZ20022838A3 (en)
DE (1) DE50104600D1 (en)
EE (1) EE200200466A (en)
ES (1) ES2231482T3 (en)
HK (1) HK1055117A1 (en)
HR (1) HRP20020688A2 (en)
HU (1) HUP0300140A3 (en)
IL (1) IL151327A0 (en)
MX (1) MXPA02007021A (en)
NO (1) NO20023978L (en)
NZ (1) NZ520926A (en)
PL (1) PL357547A1 (en)
PT (1) PT1259498E (en)
RU (1) RU2261860C2 (en)
SK (1) SK12162002A3 (en)
WO (1) WO2001062746A1 (en)
YU (1) YU56302A (en)
ZA (1) ZA200206487B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142660A1 (en) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of derivatives of C2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
DE10142659A1 (en) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Use of multiply substituted indan-1-ol. Systems for the preparation of medicaments for the prophylaxis or treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
ES2559319T3 (en) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Guanylate cliclas agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (en) 2008-10-31 2011-12-07 默沙东公司 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (en) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (en) 2011-02-25 2017-04-26 默沙东公司 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CN103764672A (en) 2011-03-01 2014-04-30 辛纳吉制药公司 Process of preparing guanylate cyclase C agonists
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20240805T1 (en) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507868A (en) * 1968-10-21 1970-04-21 Sandoz Ag Imidazo(2,1-b)thiazoles and thiazolo(3,2-a)pyrimidines
DE2640358A1 (en) * 1976-09-08 1978-03-16 Hoechst Ag THIAZOLIDE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
GB9517381D0 (en) * 1995-08-24 1995-10-25 Pharmacia Spa Aryl and heteroaryl piperazine derivatives
DE19844547C2 (en) * 1998-09-29 2002-11-07 Aventis Pharma Gmbh Polycyclic dihydrothiazoles, process for their preparation and their use as medicines
DE19908539A1 (en) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclic 2-amino-dihydrothiazole systems, processes for their preparation and their use as medicines

Also Published As

Publication number Publication date
AU781003B2 (en) 2005-04-28
NZ520926A (en) 2004-08-27
EP1259498B1 (en) 2004-11-24
EP1259498A1 (en) 2002-11-27
ES2231482T3 (en) 2005-05-16
EE200200466A (en) 2003-12-15
PT1259498E (en) 2005-02-28
PL357547A1 (en) 2004-07-26
HRP20020688A2 (en) 2004-12-31
NO20023978L (en) 2002-10-18
WO2001062746A1 (en) 2001-08-30
CN1195747C (en) 2005-04-06
CN1423640A (en) 2003-06-11
HUP0300140A3 (en) 2004-10-28
US6403624B1 (en) 2002-06-11
IL151327A0 (en) 2003-04-10
RU2002125460A (en) 2004-01-10
CZ20022838A3 (en) 2002-11-13
JP2003528825A (en) 2003-09-30
SK12162002A3 (en) 2003-02-04
CA2400698A1 (en) 2001-08-30
HK1055117A1 (en) 2003-12-24
HUP0300140A2 (en) 2003-05-28
DE50104600D1 (en) 2004-12-30
JP4898052B2 (en) 2012-03-14
NO20023978D0 (en) 2002-08-21
ZA200206487B (en) 2003-10-16
YU56302A (en) 2005-11-28
RU2261860C2 (en) 2005-10-10
BR0108605A (en) 2002-11-19
AU5615301A (en) 2001-09-03
ATE283265T1 (en) 2004-12-15
MXPA02007021A (en) 2003-03-27
KR20020079891A (en) 2002-10-19

Similar Documents

Publication Publication Date Title
US6403624B1 (en) 8,8A-dihydroindeno[1,2-D] thiazole derivatives which are substituted in the 8A-position; processes for their preparation and their use as medicaments
US6352987B2 (en) 8,8a-dihydroindeno[1,2-d]thiazole derivatives which carry in the 2-position a substituent having a sulfonamide structure or sulfone structure; processes for their preparation and their use as medicaments
US6291486B1 (en) Polycyclic Dihydrothiazoles, their preparation and use as pharmaceuticals
US6387935B1 (en) Polycyclic dihydrothiazoles having substituted alkyl radicals in the two-position, process for their preparation, and their use as pharmaceuticals
US6187801B1 (en) Polycyclic thiazole systems, processes for their preparation and pharmaceuticals comprising these compounds
US6410577B2 (en) Substituted 8,8a-dihydro-3ah-indeno[1,2-d]thiazoles, processes for their preparation and their use as medicaments
US6207689B1 (en) Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments
RU2252219C2 (en) Indeno-, naphtho-, and benzocycloheptadihydrothiazole derivatives, production thereof and uses as anorexia pharmaceuticals

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JAEHNE, GERHARD;GOSSEL, MATTHIAS;BICKEL, MARTIN;REEL/FRAME:011677/0529;SIGNING DATES FROM 20010319 TO 20010320

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789

Effective date: 20050901

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AVENTIS PHARMA DEUTSCHLAND GMBH;REEL/FRAME:016793/0789

Effective date: 20050901

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载